
		<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
		<html xmlns="http://www.w3.org/1999/xhtml">
		<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<title>G.R. No. L-27004, August 16, 1983</title>
		<style>
		body{
		margin:10px 30px 10px 30px;
		font-family:times new roman;
		font-size:110%;
		line-height:20px;
		}
		</style>
		</head>

		<body>
				209 Phil. 85
				<CENTER>				
				<H2>FIRST DIVISION</H2>
				<h4>
				G.R. No. L-27004, August 16, 1983</h4>
				<H3>PARKE, DAVIS & COMPANY, PETITIONER, VS.
DOCTOR'S PHARMACEUTICALS, INC. AND TIBURCIO S. EVALLE, IN HIS CAPACITY AS
DIRECTOR OF PATENTS, RESPONDENTS.
<br /><br />R E S O L U T I O N</H3>
				</CENTER>
				<BR><STRONG>TEEHANKEE, Acting C.J.:</STRONG>
				<BR><BR><div align="justify"><p class="BODY">In G.R. No. L-22221<a style="mso-footnote-id:ftn1" href="#_ftn1" name="_ftnref1" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[1]</sup></span></span></a>,
which involved the same parties in the instant case, the Court affirmed, in a
decision dated August 31, 1965 respondent Director of Patent's <span style="mso-bidi-font-size:13.0pt">decision </span>rendered on November 15, 1963
in <span style="mso-bidi-font-size:14.0pt">Inter <span class="SpellE">Partes</span>
Case No. </span>181 ordering petitioner Parke, Davis &amp; Co. to grant
respondent Doctor's Pharmaceuticals, Inc. a license to manufacture, use and
sell in the Philippines its own products containing petitioner's chemical
called "<span class="SpellE">chloramphenicol</span>."</p>

<p class="BODY"><span style="mso-bidi-font-size:15.0pt">The dispositive portion
of respondent official's decision reads:<o:p></o:p></span></p>

<blockquote><span style="mso-bidi-font-size:14.0pt">"Wherefore, </span>the
Respondent-Patentee is hereby ordered <span style="mso-bidi-font-size:14.0pt">to
</span><span style="mso-bidi-font-size:15.0pt">grant the Petitioner a license
under Letters Patent No. 50. </span><span style="mso-bidi-font-size:14.0pt">The
</span><span style="mso-bidi-font-size:15.0pt">parties hereto are hereby
ordered to submit to me, within THIRTY (30) days from their receipt of a copy
of this decision a licensing agreement, and </span><span style="mso-bidi-font-size:
14.0pt">in </span><span style="mso-bidi-font-size:15.0pt">default thereof, they
may submit within the same period their respective proposals. It must be shown
that </span><span style="mso-bidi-font-size:14.0pt">the </span><span style="mso-bidi-font-size:15.0pt">negotiations as </span><span style="mso-bidi-font-size:14.0pt">to </span><span style="mso-bidi-font-size:
15.0pt">the terms and conditions thereof have been made between the parties,
and if there are points of disagreement I shall fix such terms and conditions.<o:p></o:p></span></blockquote>

<blockquote>If, within the said period, no licensing agreement is filed or no negotiations
<span class="SpellE">therefor</span> transpires between the parties, I shall
issue the licensing agreement in such terms and conditions as may be just and
reasonable under the circumstances."</blockquote>

<p class="BODY">Under Section 36 of Republic Act 165 (Patent Law), the Director
of Patents is authorized, in case the parties failed to submit a licensing
agreement, to fix the terms and conditions of the license. Thus, after the <span style="mso-bidi-font-size:14.0pt">Court's </span>decision in G.R. No. <span style="mso-bidi-font-size:14.0pt">L-22221 </span>became final and <span class="SpellE">executory</span>, without the parties submitting a licensing
agreement, the Director of Patents, in a resolution dated March 25, 1966 and
amended on November 25, 1966, issued a license in favor <span style="mso-bidi-font-size:
14.0pt">of respondent company under petitioner's </span>Letters Patent No. 50
for the <span style="mso-bidi-font-size:14.0pt">patented </span>chemical "<span class="SpellE">chloramphenicol</span>", fixing the<span style="mso-bidi-font-size:
15.0pt"> </span><span style="mso-bidi-font-size:14.0pt">terms </span><span style="mso-bidi-font-size:15.0pt">and conditions </span><span style="mso-bidi-font-size:
14.0pt">thereof and declaring </span><span style="mso-bidi-font-size:15.0pt">that
the license should take effect immediately. The license provides, among others,
that respondent company should pay petitioner Parke, Davis &amp; Co., a
royalty, on all licensed products containing "<span class="SpellE">chloramphenicol</span>"
made and sold by respondent </span><span style="mso-bidi-font-size:14.0pt">company
</span><span style="mso-bidi-font-size:15.0pt">in an amount equivalent to Eight
Percent (8%) of the </span><span style="mso-bidi-font-size:14.0pt">net sales </span><span style="mso-bidi-font-size:15.0pt">which petitioner company now claims as
grossly inadequate and proposes that it be increased to 15%. Petitioner insists
that the fixing of the royalty rate by the Director of Patents is arbitrary and
without any support in evidence pointing out that the prevailing rate for
compulsory licensing on the net sales of medicines containing the patented
article is 15% and 18% of the selling price. In </span><span style="mso-bidi-font-size:
14.0pt">asking </span><span style="mso-bidi-font-size:15.0pt">for a 15% royalty
rate, petitioner alleges that it is the same rate prevailing in two compulsory
licenses for patents on medicine in Great Britain, and that in the case </span>of
J.R. <span class="SpellE">Geigy</span> <span class="SpellE">S.A.'s</span> Patent in
Canada, the rate of 12 1/2% based on net <span style="mso-bidi-font-size:15.0pt">sales
was allowed. On the other hand, respondent company points out that in a
licensing agreement between <span class="SpellE">Collett</span> &amp; Co. of
Norway </span><span style="mso-bidi-font-size:11.0pt;mso-bidi-font-weight:bold">and
<span class="SpellE">Lexal</span> </span><span style="mso-bidi-font-size:15.0pt">Laboratories
of the </span><st1:country-region><st1:place><span style="mso-bidi-font-size:
  15.0pt">Philippines</span></st1:place></st1:country-region><span style="mso-bidi-font-size:15.0pt">, royalties of 5% </span><span style="mso-bidi-font-size:13.0pt">on </span><span style="mso-bidi-font-size:
15.0pt">a vitamin preparation and 7% on a pharmaceutical pellet based on net,
sales, were agreed upon.<o:p></o:p></span></p>

<p class="BODY">It is settled that findings of fact of administrative bodies will
not be interfered with by courts of justice in the absence of a grave abuse of
discretion on the part of said bodies or unless the aforementioned findings are
not supported by substantial evidence.<a style="mso-footnote-id:ftn2" href="#_ftn2" name="_ftnref2" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[2]</sup></span></span></a></p>

<p class="BODY">The Court finds no abuse of discretion on the part of respondent
Director of Patents considering that in fixing the royalty rate he made a
compromise on the rate proposed by petitioner and those prevailing in other
countries. The <span style="mso-bidi-font-size:8.0pt">8% </span>royalty rate is
midway between the rates in <st1:country-region><st1:place>Canada</st1:place></st1:country-region>
and <st1:country-region><st1:place>Norway</st1:place></st1:country-region>. In
developing countries like the Philippines, liberal treatment in trade relations
should be afforded to local industry for as reasoned out by respondent company,
"it is so difficult to compete with the industrial giants of the drug
industry, among them being the petitioner herein, that it always is necessary
that the local drug companies should sell at much lower (than) the prices of
said foreign drug entities."<a style="mso-footnote-id:ftn3" href="#_ftn3" name="_ftnref3" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[3]</sup></span></span></a></p>

<p class="BODY">The Court agrees with then <span style="mso-bidi-font-size:14.0pt">Solicitor
</span>General, now retired Justice <span style="mso-bidi-font-size:14.0pt">Antonio
P. </span><span class="SpellE">Barredo</span> and <span style="mso-bidi-font-size:
14.0pt">then Asst. </span>Solicitor General <span class="SpellE">Pacifico</span>
de Castro, now Justice of the Supreme Court, that the 8% royalty rate is
reasonable "considering that Doctor's Pharmaceutical, Inc. is a small
manufacturing venture <span style="mso-bidi-font-size:14.0pt">compared </span>with
Parke, Davis &amp; Company, Inc. <span style="mso-bidi-font-size:14.0pt">which </span>is
a subsidiary of the huge mother firm, Parke, Davis &amp; Company of Michigan,
U.S.A." (Annex D, Petition for Review). If Doctor's is making sufficient
profit to justify an increase of royalty later, Parke, Davis &amp;<span style="mso-bidi-font-size:14.0pt"> Co., Inc. can easily </span>demand an
increase, consider<span style="mso-bidi-font-size:14.0pt">ing</span> that the
latter has access to the books <span style="mso-bidi-font-size:14.0pt">and
records </span>of the former."<a style="mso-footnote-id:ftn4" href="#_ftn4" name="_ftnref4" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[4]</sup></span></span></a></p>

<p class="BODY"><span style="mso-bidi-font-size:14.0pt">The Solicitor General
correctly states </span>that "there is no showing that <span style="mso-bidi-font-size:14.0pt">Parke, Davis &amp; Co., </span>Inc. would
tend to suffer <span style="mso-bidi-font-size:14.0pt">business losses </span>by
the <span style="mso-bidi-font-size:14.0pt">imposition of the 8% royalty nor </span>does
it appear that it would cause other effects on the <span class="SpellE">saleability</span>
of the antibiotics and consequently the health of the consuming public by the
imposition of 8%."<a style="mso-footnote-id:ftn5" href="#_ftn5" name="_ftnref5" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[5]</sup></span></span></a></p>

<p class="BODY">Petitioner's argument that respondent Director of Patents has no
authority to declare the resolution containing the licensing agreement
"shall take effect immediately" is untenable for any award, order or
decision the Patent Office is immediately <span class="SpellE">executory</span>. This
is clear from the provisions of Sec. 4, Rule 44 of the Rules of Court which pro­vides
that appeal shall not <span style="mso-bidi-font-size:14.0pt">stay </span>the
award, order or decision of the Public Service <span style="mso-bidi-font-size:
11.0pt;mso-bidi-font-weight:bold">Commission, </span>the Patent Office, and the
Agricultural Inven­tions Board. Moreover, the resolution of respondent official
was issued only after the herein parties failed to submit a licensing agreement
and had left the same to the discretion of the Director of Patents.<a style="mso-footnote-id:ftn6" href="#_ftn6" name="_ftnref6" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[6]</sup></span></span></a>
As correctly argued by the Solicitor General "to hold that said Amended
Resolution <span style="mso-bidi-font-size:14.0pt">could </span>not be made
effectively would open the door for intermin­able litigation, thus rendering
nugatory said compulsory licensing agree­ment sanctioned by the Director of
Patents, as any implementing condition imposed therein could be the subject of
litigation."</p>

<p class="BODY">At any <span style="mso-bidi-font-size:24.0pt">r</span>ate, the
letter patent granted to petitioner on the particular process was to expire
after seventeen years, and having been granted on <st1:date year="1950" day="9" month="2">February 9, 1950</st1:date>, the <span style="mso-bidi-font-size:
10.0pt;mso-bidi-font-weight:bold">same </span>already expired on <st1:date year="1967" day="9" month="2">February 9, 1967</st1:date>.</p>

<p class="BODY"><b>WHEREFORE,</b> the instant petition is hereby dismissed and
the questioned resolution of the Director of Patents is hereby affirmed in all
respects. No costs.</p>

<span style="font-style:italic"><span class="SpellE">Melencio</span>-Herrera, <span class="SpellE">Plana</span>,
Vasquez, <span class="SpellE">Relova</span>, <span style="font-style:normal">and</span>
Gutierrez, Jr., JJ., <span style="font-style:normal">concur.</span></span><br>

<br><br><hr size="1" width="33%" align="left">

<!--[endif]-->



<p class="FOOTNOTES"><a style="mso-footnote-id:ftn1" href="#_ftnref1" name="_ftn1" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[1]</sup></span></span></a>
14 <span style="mso-bidi-font-size:3.0pt">SCRA</span><span style="mso-bidi-font-size:
11.0pt;mso-bidi-font-weight:bold"> 1</span><span style="mso-bidi-font-size:
6.0pt">053.</span></p>





<p class="FOOTNOTES"><a style="mso-footnote-id:ftn2" href="#_ftnref2" name="_ftn2" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[2]</sup></span></span></a>
La <span class="SpellE">Mallorca</span> &amp; <span class="SpellE">Pampanga</span>
Bus Co. <i><span style="mso-bidi-font-size:14.0pt">vs</span></i><span style="mso-bidi-font-size:14.0pt">. </span>Mercado, 15 SCRA 343; <span class="SpellE">Halili</span> <i>vs</i>. <span class="SpellE"><span style="mso-bidi-font-size:15.0pt">Daplas</span></span><span style="mso-bidi-font-size:
15.0pt">, 14 SCRA 14.</span></p>





<p class="FOOTNOTES"><a style="mso-footnote-id:ftn3" href="#_ftnref3" name="_ftn3" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[3]</sup></span></span></a> <span style="mso-bidi-font-size:15.0pt">Brief for the Respondent Doctor's
Pharmaceuticals, Inc., p. 13.</span></p>





<p class="FOOTNOTES"><a style="mso-footnote-id:ftn4" href="#_ftnref4" name="_ftn4" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[4]</sup></span></span></a> <span style="mso-bidi-font-size:15.0pt">P. 43, <span class="SpellE"><i>Rollo</i></span>.</span></p>





<p class="FOOTNOTES"><a style="mso-footnote-id:ftn5" href="#_ftnref5" name="_ftn5" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[5]</sup></span></span></a> <i><u>Ibid</u></i>.</p>





<p class="FOOTNOTES"><a style="mso-footnote-id:ftn6" href="#_ftnref6" name="_ftn6" title=""><span class="MsoFootnoteReference"><span style="font-size:8.0pt"><sup style="color: rgb(255, 0, 0);">[6]</sup></span></span></a>
Annex "D", p. 30, <span class="SpellE"><i>Rollo</i></span>.</p>





</div>
				<BR><BR>
				
				<HR SIZE='1px' style='margin-top:20px;'>
				<br />
				<center>
				<small style='font-size:10px;line-height:11px;color:#666666;'>
				<!--
				Date created: November 27, 2014
				-->
				</small>
				</center>	
		</body>
		</html>
		